1463.1: A Phase 1, open-label, dose-finding study of CD137/FAP bispecific agonist antibody (BI 765179) as monotherapy and in combination with ezabenlimab (PD-1 inhibitor) in patients with advanced solid cancers

NCT04958239. https://clinicaltrials.gov/ct2/show/NCT04958239. Accessed September 2023.